Results 201 to 210 of about 297,240 (266)

One risk assessment for genetically modified plants. [PDF]

open access: yesFront Bioeng Biotechnol
Koch M   +4 more
europepmc   +1 more source

Predictive Ability of Plasma p‐tau217 for β‐Amyloid Status: A Prospective Multicenter Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma tau phosphorylated at threonine 217 (p‐tau217) measured with fully automated platforms has shown high accuracy for Alzheimer's disease (AD) diagnosis, but real‐world multicenter data remain limited. We aimed to validate the diagnostic performance of p‐tau217 for identifying AD pathology in a real‐world multicenter cohort ...
Miquel Massons   +33 more
wiley   +1 more source

Safety evaluation of the food enzyme endo-1,4-β-xylanase from the genetically modified <i>Bacillus licheniformis</i> strain NZYM-FX. [PDF]

open access: yesEFSA J
EFSA Panel on Food Enzymes (FEZ)   +15 more
europepmc   +1 more source

White Matter Hyperintensity Burden and Short‐Interval Change Associated With Sleep Apnoea in the UK Biobank

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Purpose White matter hyperintensities (WMH) are a core neuroimaging marker of cerebral small vessel disease (CSVD). Sleep apnoea (SA) is a recognized vascular risk factor, but its associations with regional WMH burden, short‐interval WMH change and cognitive performance in population‐based cohorts remain incompletely defined. We
Peng Cheng   +4 more
wiley   +1 more source

Safety evaluation of the food enzyme glucan 1,4-α-glucosidase from the non-genetically modified <i>Aspergillus niger</i> strain AE-GN. [PDF]

open access: yesEFSA J
EFSA Panel on Food Enzymes (FEZ)   +20 more
europepmc   +1 more source

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane   +19 more
wiley   +1 more source

Challenges and opportunities in the regulatory landscape of genetically modified crops in the European Union. [PDF]

open access: yesFront Bioeng Biotechnol
Garcia-Alonso M   +5 more
europepmc   +1 more source

Genetically Modified Mouse Models for Sarcoma Research: A Comprehensive Review. [PDF]

open access: yesCurr Oncol Rep
Remiszewski P   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy